reports
Taysha Gene Therapies Presents New Supplemental Data Analysis from Par...
Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase 1/2 Trials for TSHA-102 in Rett Syndrome at the 54th CNS Annual Meeting Previously disclosed 100% response rate across all 10 patients in Part A for pivotal trial primary endpoint of gain/regain of ≥ one natural history defined developmental milestone assessed via video-evidenced review by independent central raters New supplemental analysis of validated, structured efficacy scales provides supportive evidence of additional functional gains, with 100% of patients demonstrating multiple skill gai...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, Oct. 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on October 1, 2025, the Compensation Committee of Taysha's Board of Directors granted seven new employees, in the aggregate, options to purchase 1,289,600 shares of the Company's common stock in conne...
Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation a...
Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome Breakthrough Therapy designation granted based on FDA’s review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized FDA alignment on REVEAL pivotal trial protocol and SAP following resolution of remaining clinical and statistical queries to IND application amendment; on track to begin patient enrollment in Q4 2025 Key pivotal trial design elements remain unchanged, includin...
Calavo Growers, Inc. Announces Third Quarter and Nine-Month Period End...
Calavo Growers, Inc. Announces Third Quarter and Nine-Month Period Ended July 31, 2025 Financial Results SANTA PAULA, Calif., Sept. 09, 2025 (GLOBE NEWSWIRE) -- (Nasdaq-GS: CVGW), a global leader in sourcing, packing and distribution of fresh avocados, tomatoes, papayas and processing of guacamole and other avocado products, today reported its financial results for the third fiscal quarter and nine-month period ended July 31, 2025. Third Quarter Financial Overview Total net sales were $178.8 million, a decrease of less than one percent from the prior year. Fresh segment sales were...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, Sept. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on September 2, 2025, the Compensation Committee of Taysha's Board of Directors granted five new employees, in the aggregate, options to purchase 225,000 shares of the Company's common stock in conne...
Calavo Growers to Report Third Quarter 2025 Financial Results
Calavo Growers to Report Third Quarter 2025 Financial Results SANTA PAULA, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- (Nasdaq-GS: CVGW), a global leader in sourcing, packing and distribution of fresh avocados, tomatoes, papayas and processing of guacamole and other avocado products, today announced that it plans to release financial results for the fiscal third quarter ended July 31, 2025, after the market closes on Tuesday, September 9, 2025. About Calavo Growers, Inc.Calavo Growers, Inc. (Nasdaq: CVGW) is a global leader in the processing and distribution of avocados, tomatoes, papayas...
Taysha Gene Therapies Reports Second Quarter 2025 Financial Results an...
Taysha Gene Therapies Reports Second Quarter 2025 Financial Results and Provides Corporate Update Commenced site activation for REVEAL pivotal trial in accordance with previously aligned upon key design elements, following receipt of No Objection Letter (NOL) from Health Canada and feedback from the FDA; patient enrollment anticipated to begin in Q4 2025 High dose and low dose TSHA-102 continue to be generally well tolerated with no treatment-related SAEs or DLTs in the 12 patients treated in Part A of REVEAL Phase 1/2 trials as of August 2025 data cutoff Part A data from REVEAL Phase 1/2...
Taysha Gene Therapies to Release Second Quarter 2025 Financial Results...
Taysha Gene Therapies to Release Second Quarter 2025 Financial Results and Host Conference Call and Webcast on August 12 DALLAS, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it will report its financial results for the second quarter ended June 30, 2025, and host a corporate update conference call and webcast on Tuesday, August 12, 2025, ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on August 1, 2025, the Compensation Committee of Taysha's Board of Directors granted one new employee an option to purchase 90,000 shares of the Company's common stock in connection with their employm...
Landmark Bancorp, Inc. Announces Second Quarter 2025 Earnings per Shar...
Landmark Bancorp, Inc. Announces Second Quarter 2025 Earnings per Share of $0.75 Declares Cash Dividend of $0.21 per Share Manhattan, KS, July 24, 2025 (GLOBE NEWSWIRE) -- Landmark Bancorp, Inc. (“Landmark”; Nasdaq: LARK) reported diluted earnings per share of $0.75 for the second quarter of 2025, compared to $0.81 per share in the first quarter of 2025 and $0.52 per share in the same quarter of the prior year. Net earnings for the second quarter totaled $4.4 million, compared to $4.7 million in the prior quarter and $3.0 million in the second quarter of 2024. For the three months ended J...
Landmark Bancorp, Inc. Announces Conference Call to Discuss Second Qua...
Landmark Bancorp, Inc. Announces Conference Call to Discuss Second Quarter 2025 Earnings Manhattan, KS, July 11, 2025 (GLOBE NEWSWIRE) -- Landmark Bancorp, Inc. (Nasdaq: LARK) announced that it will release earnings for the second quarter of 2025 after the market closes on Thursday, July 24, 2025. The Company will host a conference call to discuss these results on Friday, July 25, 2025 at 10:00 am (CT). Investors may listen to the Company’s earnings call via telephone by dialing (833) 470-1428 and using access code 703723. Investors are encouraged to call the dial-in number at least 5 min...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, July 03, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on July 1, 2025, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, options to purchase 30,000 shares of the Company's common stock in connection wi...
- Jonathan Moreland
TRS TRIMAS CORPORATION
TLYS TILLYS
TCBI TEXAS CAPITAL BANCSHARES INC.
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
MTH MERITAGE HOMES CORPORATION
INUV INUVO INC
FFIN FIRST FINANCIAL BANKSHARES INC
CAL CALERES INC.
CABO CABLE ONE INC.
PATK PATRICK INDUSTRIES INC.
ADC AGREE REALTY CORPORATION
TTI TETRA TECHNOLOGIES INC.
UEIC UNIVERSAL ELECTRONICS INC.
VRA VERA BRADLEY INC.
CIA CITIZENS INC. CL A
CC CHEMOURS CO.
IOVA IOVANCE BIOTHERAPEUTICS INC
QTRX QUANTERIX CORPORATION
RSSS RESEARCH SOLUTIONS
BHC BAUSCH HEALTH COMPANIES INC.
BBDC BARINGS BDC INC.
YMAB Y-MABS THERAPEUTICS
ETON ETON PHARMACEUTICALS
IMUX IMMUNIC INC
BLDR BUILDERS FIRSTSOURCE
FNWB INC.
AMPY FIRST NORTHWEST BANCORP
DCTH AMPLIFY ENERGY
ENX DELCATH SYSTEMS
TSHA EATON VANCE NEW YORK MUNICIPAL BOND FUND
SMMT TAYSHA GENE THERAPIES
HLMN SUMMIT THERAPEUTICS INC
COOK HILLMAN SOLUTIONS CORP.
AIRS TRAEGER
GECC INC.
TYRA AIRSCULPT TECHNOLOGIES INC
NNUP GREAT ELM CAPITAL CORP
BHRB TYRA BIOSCIENCES INC
DPG NOCOPI TECHS INC
RNXT BURKE & HERBERT BANK & TR/VA
GTE DUFF & PHELPS GLOBAL UTIL INCOME FD
SRBK RENOVORX INC
NKGN GRAN TIERRA ENERGY INC.
MNR SR BANCORP INC
NBBK NKGEN BIOTECH INC
NCDL MACH NATURAL RESOURCES LP
SDHY NB BANCORP INC.
ABL NUVEEN CHURCHILL DIRECT LENDING CORP
WHLR PGIM SHORT DURATION HIGH YIELD OPPORTUNITIES FUND
ABACUS GLOBAL MANAGEMENT INC.
WHEELER REAL ESTATE INVESTMENT TRUST INC.
Calavo Growers, Inc. Announces Receipt of Unsolicited Proposal
Calavo Growers, Inc. Announces Receipt of Unsolicited Proposal SANTA PAULA, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- (Nasdaq-GS: CVGW) (the “Company” or “Calavo”), a global leader in sourcing, packing and distribution of fresh avocados, tomatoes, papayas and processing of guacamole and other avocado products, today announced that it has received a non-binding, indicative proposal to acquire all of the outstanding shares of the Company for consideration nominally valued at $32.00 per share of the Company’s common stock, consisting of a combination of stock of the proposing party and cash...
Calavo Growers, Inc. Announces Second Quarter and Six-Month Period End...
Calavo Growers, Inc. Announces Second Quarter and Six-Month Period Ended April 30, 2025 Financial Results SANTA PAULA, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- (Nasdaq-GS: CVGW), a global leader in sourcing, packing and distribution of fresh avocados, tomatoes, papayas and processing of guacamole and other avocado products, today reported its financial results for the second fiscal quarter and six-month period ended April 30, 2025. Second Quarter Financial Overview Total net sales were $190.5 million, a 3.3% increase from the prior year quarter. Fresh segment sales were $174.7 mi...
- Jonathan Moreland
WSR WHITESTONE REIT
TTSH TILE SHOP HOLDINGS INC.
TRS TRIMAS CORPORATION
TLYS TILLYS
TCBI TEXAS CAPITAL BANCSHARES INC.
SHEN SHENANDOAH TELECOMMUNICATIONS COMPANY
MCY MERCURY GENERAL CORPORATION
FLO FLOWERS FOODS INC.
CTBI COMMUNITY TRUST BANCORP INC.
BUSE FIRST BUSEY CORPORATION
PATK PATRICK INDUSTRIES INC.
VFF VILLAGE FARMS INTERNATIONAL IN
SWM SCHWEITZER-MAUDUIT INTERNATIONAL INC.
CIA CITIZENS INC. CL A
BDL FLANIGAN'S ENTERPRISES INC.
CC CHEMOURS CO.
NHF NEXPOINT CREDIT STRATEGIES FUN
IOVA IOVANCE BIOTHERAPEUTICS INC
RSSS RESEARCH SOLUTIONS
RFL RAFAEL HOLDINGS CL B
BBDC BARINGS BDC INC.
YMAB Y-MABS THERAPEUTICS
REZI RESIDEO TECHNOLOGIES
IMUX INC.
FNWB IMMUNIC INC
XRX FIRST NORTHWEST BANCORP
AMPY XEROX HOLDINGS CORPORATION
VLA AMPLIFY ENERGY
TSHA ARBOR METALS
INNV TAYSHA GENE THERAPIES
SMMT INNOVAGE HOLDING
AFBI SUMMIT THERAPEUTICS INC
COOK AFFINITY BANCSHARES
TYRA INC.
BHRB TRAEGER
DPG INC.
VFC TYRA BIOSCIENCES INC
UHG BURKE & HERBERT BANK & TR/VA
GENK DUFF & PHELPS GLOBAL UTIL INCOME FD
SRBK VF CORPORATION
NKGN UNITED HOMES GROUP INC
NCDL GEN RESTAURANT GROUP INC
SDHY SR BANCORP INC
NEO NKGEN BIOTECH INC
JEQ NUVEEN CHURCHILL DIRECT LENDING CORP
LION PGIM SHORT DURATION HIGH YIELD OPPORTUNITIES FUND
SLS NEO CORPORATE PUBLIC COMPANY LIMITED
ABL THE JAPAN EQUITY FUND
INC.
LIONSGATE STUDIOS CORP
SELLAS LIFE SCIENCES GROUP INC
ABACUS GLOBAL MANAGEMENT INC.
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing ...
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) DALLAS, June 06, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 2, 2025, the Compensation Committee of Taysha's Board of Directors granted two new employees, in the aggregate, options to purchase 401,000 shares of the Company's common stock in connection w...
- Jonathan Moreland
TDOC TELADOC HEALTH INC.
VFF VILLAGE FARMS INTERNATIONAL IN
SWM SCHWEITZER-MAUDUIT INTERNATIONAL INC.
CCO CLEAR CHANNEL OUTDOOR HOLDINGS INC
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
VLA ARBOR METALS
DLHC DALEIGH HOLDINGS CORP
IMNM IMMUNOME
TSHA TAYSHA GENE THERAPIES
AFBI AFFINITY BANCSHARES
EVM INC.
SDHY EATON VANCE INSD CALIF MUN BD FD
PGIM SHORT DURATION HIGH YIELD OPPORTUNITIES FUND
Taysha Gene Therapies Announces Details for Oral Presentations at the ...
Taysha Gene Therapies Announces Details for Oral Presentations at the 2025 IRSF Rett Syndrome Scientific Meeting Reviewing Recent Updates from the TSHA-102 Clinical Program Recently disclosed clinical cohort data from high (1x1015 total vg) and low dose (5.7x1014 total vg) TSHA-102 from REVEAL adolescent/adult and pediatric Phase 1/2 trials Caregiver research regarding gain/regain of developmental milestones supporting alignment with FDA on primary endpoint in the pivotal Part B trial of TSHA-102 Previously disclosed preclinical data supporting broad biodistribution across brain and spina...
- Dave Nicoski
- Ross LaDuke
RCKY ROCKY BRANDS
PZZA PAPA JOHN'S INTERNATIONAL INC.
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
MU MICRON TECHNOLOGY INC.
MSA MSA SAFETY INC.
MPC MARATHON PETROLEUM CORPORATION
MCHP MICROCHIP TECHNOLOGY INCORPORATED
KOP KOPPERS HOLDINGS INC.
GPC GENUINE PARTS COMPANY
DLTR DOLLAR TREE INC.
DG DOLLAR GENERAL CORPORATION
CVGW CALAVO GROWERS INC.
BEN FRANKLIN RESOURCES INC.
AAP ADVANCE AUTO PARTS INC.
MEG. MEG ENERGY CORP.
FSLR FIRST SOLAR INC.
KALU KAISER ALUMINUM CORPORATION
PVH PVH CORP.
NHC NATIONAL HEALTHCARE CORP.
ELF E.L.F. BEAUTY INC.
DK DELEK US HOLDINGS INC
SCPH SCPHARMACEUTICALS INC
MTW MANITOWOC COMPANY INC.
TTEC TTEC HOLDINGS INC.
ADNT ADIENT PLC
ULBI ULTRALIFE
ELAN ELANCO ANIMAL HEALTH INC.
OCGN OCUGEN INC
ITOS ITEOS THERAPEUTICS
ETWO E2OPEN PARENT HOLDINGS INC (A)
PAX PATRIA INVESTMENTS
VAL VALARIS LTD
DINO HOLLYFRONTIER CORP
NE NOBLE CORP (NEW)
ADCT ADC THERAPEUTICS SA
SVV SAVERS VALUE VILLAGE INC
GUTS FRACTYL HEALTH INC
LRCX LAM RESEARCH CORPORATION
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.